Related Experiment Video
Updated: Nov 20, 2025
08:52
Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
Published on: January 19, 2018
14.3K
Engineered nanomedicines for tumor vasculature blockade therapy
Duoyi Zhao1,2, Xu Huang2,3, Zhiyu Zhang1
1Department of Orthopedics, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
|January 22, 2021
Summary
Engineered nanoparticles enhance tumor vasculature blockade therapy (TVBT) by improving drug delivery and enabling combination treatments. This approach addresses limitations of traditional TVBT for solid tumors.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Tumor vasculature blockade therapy (TVBT) shows promise for solid tumors but faces challenges like low selectivity and drug resistance.
- Engineered nanoparticles offer improved circulation, targeting, and controlled release of TVBT agents.
Purpose of the Study:
- To summarize the progress of engineered nanomedicines in TVBT.
- To discuss current limitations and future directions for nanomedicine-based TVBT.
Main Methods:
- Review of current literature on engineered nanomedicines for TVBT.
- Analysis of combination therapies involving nanomedicines and TVBT modalities.
Main Results:
- Engineered nanomedicines can overcome TVBT limitations through enhanced delivery and targeting.
- Nanomedicines facilitate combination therapies (chemotherapy, radiotherapy, etc.) with TVBT.
Conclusions:
- Engineered nanomedicines represent a significant advancement for TVBT in oncologic disease.
- Further development is needed to address deficiencies and optimize nanomedicine-based TVBT strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:10Mechanism of Angiogenesis
6.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
01:24Regulation of Angiogenesis and Blood Supply
3.1K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.1K